| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03537547 Details | 2020-06-05 Interventional | 4 | 6 | Antidepressive … Antipsychotic A… Psychotropic Dr… Depression Depressive Diso… Depressive Diso… Depression, Uni… Depressive Epis… Major Depressiv… | Per sponsor and PI institution discussions - | |||
| NCT02573857 Details | 2020-06-05 Interventional | 1/2 | 16 | Artefenomel Malaria | - - | |||
| NCT04347512 Details | 2020-06-04 Interventional | 3 | 0 | Azithromycin Hydroxychloroqu… COVID-19 Sars-CoV-2, Com… | In view of the notices concerning hydroxychloroquine issued by the regulatory authorities, we
withdraw the protocol - | |||
| NCT04001231 Details | 2020-06-04 Interventional | 1 | 0 | Exenatide Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes | The study is stopped based upon strategic considerations impacting the clinical development of
exenatide once-weekly suspension in China - | |||
| NCT03115320 2016-003959-29 Details | 2020-06-04 Interventional | 4 | 62 | Chorionic Gonad… Infertility | High cancellation rate in LH test group in interim analysis - | |||
| NCT00958139 Details | 2020-06-04 Interventional | 3 | 61 | Permethrin Lyme Disease | After year 1, there was insufficient statistical power to detect a difference in the primary
outcome measure during planned study period. - | |||
| NCT04184518 2019-001045-40 Details | 2020-06-02 Interventional | 2 | 0 | Cediranib Durvalumab Melanoma Uveal Neoplasms Metastatic Canc… Uveal Melanoma | The Cediranib producer laboratory decided to stop the development of this product. - | |||
| NCT03718143 Details | 2020-06-02 Interventional | 2 | 6 | Adavosertib Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Primary Myelofi… Syndrome Acute Myeloid L… Myelofibroses | Safety concerns - | |||
| NCT03411473 Details | 2020-06-02 Interventional | 2 | 2 | Pembrolizumab Carcinoma, Non-… NSCLC Stage IV | Trial will not proceed due to changes in the treatment landscape. - | |||
| NCT02842125 Details | 2020-06-02 Interventional | 1/2 | 4 | Capecitabine Nivolumab Pembrolizumab Recurrence Metastatic Soli… Recurrent Head … | Arm C rolled into parallel study; Arms A and B halted for greater efficacy in Arm C - | |||
| NCT01796470 Details | 2020-06-02 Interventional | 2 | 66 | Idelalisib Hematologic Neo… Leukemia, Lymph… Lymphoma Lymphoma, Large… Lymphoma, Mantl… Chronic Lymphoc… Diffuse Large B… Indolent Non-Ho… Mantle Cell Lym… | Study was terminated due to safety measures. As a result of the early termination of the trial for safety, the efficacy endpoints were not evaluable due to insufficient treatment exposure. | |||
| NCT00288522 2004-003937-14 Details | 2020-06-02 Interventional | 2 | 5 | Lanreotide Eye Diseases Graves Ophthalm… Thyroid Disease… Thyroid-Associa… | - - | |||
| NCT04114630 2019-001820-36 Details | 2020-06-01 Interventional | 3 | 0 | Erenumab Migraine Disord… Migraine | No patients were enrolled and global prioritization of pipeline and research strategy - | |||
| NCT00896025 Details | 2020-06-01 Interventional | 4 | 255 | Acetylcysteine N-monoacetylcys… Hepatic Insuffi… Liver Failure Liver Failure, … Acute Liver Fai… Fulminant Hepat… | This observational study was stopped after 140 patients were enrolled, no more funds available
to continue. Early termination lead to zero subjects analyzed. | |||
| NCT03050398 Details | 2020-05-28 Interventional | 3 | 8 | Letrozole Breast Neoplasm… Breast Cancer | GCP issues. - | |||
| NCT02648711 Details | 2020-05-28 Interventional | 1 | 41 | Bevacizumab Leucovorin Oxaliplatin Neoplasms Solid Tumors | Company decision - | |||
| NCT02405585 Details | 2020-05-28 Interventional | 2 | 10 | Fluorouracil Gemcitabine Irinotecan Leucovorin Oxaliplatin Pancreatic Neop… Pancreatic Canc… Pancreatic Carc… | - - | |||
| NCT02389985 Details | 2020-05-28 Interventional | 1/2 | 30 | Paclitaxel Ovarian Cancer | Company decision - | |||
| NCT01836432 Details | 2020-05-28 Interventional | 3 | 302 | Albumin-Bound P… Capecitabine Fluorouracil Folfirinox Gemcitabine Irinotecan Leucovorin Oxaliplatin Paclitaxel Neoplasms Pancreatic Neop… Locally Advance… Pancreatic Canc… Pancreatic Carc… | Company decision - | |||
| NCT01826448 Details | 2020-05-28 Interventional | 1 | 13 | Vemurafenib Melanoma Stage III or St… V600-mutated BR… V600-mutated BR… | No activity was observed. BRAFi-naïve participants should have received triple combination
treatment (including MEK inhibitor). Continuation was not justified. This study was terminated due to business decision before the planned sample size was reached; therefore, the planned outcome measure cannot be evaluated. |